4 Healthcare Stock Stories For Weekend Investment Wellness

Anthera Pharmaceuticals (NASDAQ:ANTH): Current price $0.65

Anthera said that it has begun the CHABLIS-SC1 Phase 3 study of blisibimod, which is a novel inhibitor of B-Cell Activating Factor for treating  systemic lupus erythematosus (lupus). Lupus is a chronic autoimmune disease, which often causes severe skin rash, fatigue, joint pain and major organ complications. Anthera is a biopharmaceutical firm that deveops drugs to treat serious diseases linked with inflammation and autoimmune disorders.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ANTH

Biogen IDEC (NASDAQ:BIIB): Current price $191.62

Late Wednesday, the FDA cleared Tecfidera (dimethyl fumarate) capsules to treat adults suffering from relapsing forms of multiple sclerosis. The condition is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body, being among the most common causes of neurological disability in young adults, and appears more frequently in women than men.
Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.
BIIB

Merck & Co. (NYSE:MRK): Current price $44.02

Merck reports that the Biologics License Application for its investigational Timothy grass pollen allergy immunotherapy tablet, has been accepted for review by the FDA. In March, the firm also submitted a BLA to the FDA for its investigational ragweed pollen tablet. The application for Merck’s grass pollen tablet is supported by Phase III trials that studied the safety and efficacy of the investigational product, including a long-term, multi-season trial.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

MRK

Life Technologies Corporation (NASDAQ: LIFE): Current price $64.33

The firm has announced that its Applied Biosystems 3500xL Dx Genetic Analyzer has been approved by the State Food and Drug Administration of China for the clinical diagnostic use there and the debut of 10 Assays from its joint venture with Daan Gene. The development represents a major extension of Life Technologies’ abilities to serve the clinical end market in China with Sanger-based solutions. The 3500xL Dx is an automated 24 capillary-based Sanger Sequencer created for a wide range of sequencing applications. It delivers high quality performance, higher throughput and heightened productivity for clinical laboratories around the world.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

LIFE

Don’t Miss: Is UnitedHealth Suddenly a Dangerous Investment?

More Articles About:   , ,  

More from The Cheat Sheet